Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascletis Pharma, Inc. ( (HK:1672) ) just unveiled an announcement.
Ascletis Pharma Inc. announced its unaudited interim results for the six months ending June 30, 2025, highlighting a significant reduction in losses by 32.5% compared to the previous year, despite increased R&D costs. The company made notable progress in its metabolic disease pipeline, including advancements in obesity and acne treatments, underscoring its strong R&D capabilities and commitment to addressing unmet clinical needs. Ascletis has sufficient cash reserves to support its operations and research activities until 2029.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biomedical company incorporated in the Cayman Islands, focusing on addressing global unmet medical needs in metabolic diseases. The company is committed to developing innovative treatments and has a strong pipeline in metabolic, immune, and exploratory indications.
Average Trading Volume: 6,096,893
Technical Sentiment Signal: Buy
Current Market Cap: HK$15.12B
For a thorough assessment of 1672 stock, go to TipRanks’ Stock Analysis page.